Wayne Markowitz, the General Manager and Senior Vice President of Surgical at Edwards Lifesciences Corp (NYSE:EW), a $42.4 billion medical devices company with an impressive "GREAT" InvestingPro Financial Health score, recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On December 6, Markowitz sold 583 shares of common stock at a price of $73.27 per share, amounting to a total transaction value of $42,716. Following this transaction, Markowitz holds 9,493 shares directly. This sale reflects changes in beneficial ownership but does not account for other securities Markowitz may own. The company trades at an attractive P/E ratio of 10.4x and maintains strong financials with more cash than debt on its balance sheet. For comprehensive insider trading analysis and additional ProTips, visit InvestingPro, where you'll find detailed research reports covering 1,400+ US stocks.
In other recent news, Edwards Lifesciences has been the focus of several analyst outlook adjustments. TD Cowen maintained a Hold rating on the company's stock, raising the price target from $70 to $75, following the company's annual investor day where Edwards Lifesciences presented a positive multiyear outlook. The company reiterated its 2024 guidance and introduced its 2025 projections, which align with current market estimates.
RBC Capital Markets also maintained an Outperform rating on Edwards Lifesciences, increasing the stock's price target to $85 from $80, following the company's presentation of its 2025 outlook. The company's forecast predicted an 8-10% revenue growth, higher than the consensus estimate of 7.8%.
Bernstein SocGen Group, on the other hand, maintained its Market Perform rating on Edwards Lifesciences with a steady price target of $72.00. The company has set a Transcatheter Aortic Valve Replacement (TAVR) growth forecast at 5%-7% for 2025, seen as cautiously conservative.
Truist Securities increased the price target for Edwards Lifesciences to $78 from $70, while maintaining a Hold rating. The company's 2025 earnings per share (EPS) guidance aligns with consensus estimates, charting a course towards double-digit revenue and EPS growth starting in 2026.
Lastly, Canaccord Genuity maintained a Hold rating on Edwards Lifesciences and increased the price target to $68 from $63. The company presented its financial outlook for 2025 and discussed its anticipated growth drivers during its annual investor conference.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.